Try a new search

Format these results:

Searched for:

in-biosketch:true

person:mdk230

Total Results:

129


Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer

Ben-Ami, Roni; Wang, Qiao-Li; Zhang, Jinming; Supplee, Julianna G; Fahrmann, Johannes F; Lehmann-Werman, Roni; Brais, Lauren K; Nowak, Jonathan; Yuan, Chen; Loftus, Maureen; Babic, Ana; Irajizad, Ehsan; Davidi, Tal; Zick, Aviad; Hubert, Ayala; Neiman, Daniel; Piyanzin, Sheina; Gal-Rosenberg, Ofer; Horn, Amit; Shemer, Ruth; Glaser, Benjamin; Boos, Natalia; Jajoo, Kunal; Lee, Linda; Clancy, Thomas E; Rubinson, Douglas A; Ng, Kimmie; Chabot, John A; Kastrinos, Fay; Kluger, Michael; Aguirre, Andrew J; Jänne, Pasi A; Bardeesy, Nabeel; Stanger, Ben; O'Hara, Mark H; Till, Jacob; Maitra, Anirban; Carpenter, Erica L; Bullock, Andrea J; Genkinger, Jeanine; Hanash, Samir M; Paweletz, Cloud P; Dor, Yuval; Wolpin, Brian M
OBJECTIVE:Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC when curative treatments can be employed. DESIGN:To assess circulating marker discrimination in training, testing and validation patient cohorts (total n=426 patients), plasma markers were measured among PDAC cases and patients with chronic pancreatitis, colorectal cancer (CRC), and healthy controls. Using CA19-9 as an anchor marker, measurements were made of two protein markers (TIMP1, LRG1) and cell-free DNA (cfDNA) pancreas-specific methylation at 9 loci encompassing 61 CpG sites. RESULTS:Comparative methylome analysis identified nine loci that were differentially methylated in exocrine pancreas DNA. In the training set (n=124 patients), cfDNA methylation markers distinguished PDAC from healthy and CRC controls. In the testing set of 86 early stage PDAC and 86 matched healthy controls, CA19-9 had an area under the receiver operating characteristic curve (AUC) of 0.88 (95% CI 0.83 to 0.94), which was increased by adding TIMP1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.06), LRG1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02) or exocrine pancreas-specific cfDNA methylation markers at nine loci (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02). In the validation set of 40 early stage PDAC and 40 matched healthy controls, a combined panel including CA19-9, TIMP1 and a 9-loci cfDNA methylation panel had greater discrimination (AUC 0.86, 95% CI 0.77 to 0.95) than CA19-9 alone (AUC 0.82; 95% CI 0.72 to 0.92). CONCLUSION:A combined panel of circulating markers including proteins and methylated cfDNA increased discrimination compared with CA19-9 alone for early stage PDAC.
PMCID:10958271
PMID: 38123998
ISSN: 1468-3288
CID: 5825872

Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant lesions in the pancreas: an analysis using the National Cancer Database

Jung, Hye-Sol; Lee, Mirang; Han, Youngmin; Thomas, Alexander S; Yun, Won-Gun; Cho, Young J; Kluger, Michael D; Jang, Jin-Young; Kwon, Wooil
BACKGROUND:Invasive carcinomas arising from premalignant lesions are currently staged by the same criteria as conventional pancreatic ductal adenocarcinoma. METHODS:Clinicopathologic information and survival data were extracted through a thorough search of histology codes from National Cancer Database (2006-2016). A total of 723 patients with invasive intraductal papillary mucinous neoplasm and mucinous cystic neoplasm were analyzed. RESULTS:The median age was 67 years, and 351 patients (48.5%) were male. There were 212 (29.3%), 232 (32.1%), 272 (37.6%), and 7 (1.0%) patients with T1, T2, T3, and T4 classification. Extrapancreatic extension (EPE) was present in 284 (39.3%). Age (HR = 1.504, 95% CI 1.196-1.891), R1 or R2 resection (HR = 1.585, 95% CI 1.175-2.140), and EPE (HR = 1.598, 95% CI 1.209-2.113) were independent prognostic factors for overall survival. Size criteria did not significantly affect survival. The median survival was 115.9 months for patients without EPE, compared to 34.2 months for those with EPE. EPE discriminated survival better than tumor size. DISCUSSION:The T classification of the eighth edition AJCC staging system is not adequate for invasive carcinomas associated with premalignant lesions of the pancreas. They merit a separate, dedicated staging system that uses appropriate prognostic factors.
PMID: 38114399
ISSN: 1477-2574
CID: 5786992

Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Wasko, Urszula N; Jiang, Jingjing; Dalton, Tanner C; Curiel-Garcia, Alvaro; Edwards, A Cole; Wang, Yingyun; Lee, Bianca; Orlen, Margo; Tian, Sha; Stalnecker, Clint A; Drizyte-Miller, Kristina; Menard, Marie; Dilly, Julien; Sastra, Stephen A; Palermo, Carmine F; Hasselluhn, Marie C; Decker-Farrell, Amanda R; Chang, Stephanie; Jiang, Lingyan; Wei, Xing; Yang, Yu C; Helland, Ciara; Courtney, Haley; Gindin, Yevgeniy; Muonio, Karl; Zhao, Ruiping; Kemp, Samantha B; Clendenin, Cynthia; Sor, Rina; Vostrejs, William P; Hibshman, Priya S; Amparo, Amber M; Hennessey, Connor; Rees, Matthew G; Ronan, Melissa M; Roth, Jennifer A; Brodbeck, Jens; Tomassoni, Lorenzo; Bakir, Basil; Socci, Nicholas D; Herring, Laura E; Barker, Natalie K; Wang, Junning; Cleary, James M; Wolpin, Brian M; Chabot, John A; Kluger, Michael D; Manji, Gulam A; Tsai, Kenneth Y; Sekulic, Miroslav; Lagana, Stephen M; Califano, Andrea; Quintana, Elsa; Wang, Zhengping; Smith, Jacqueline A M; Holderfield, Matthew; Wildes, David; Lowe, Scott W; Badgley, Michael A; Aguirre, Andrew J; Vonderheide, Robert H; Stanger, Ben Z; Baslan, Timour; Der, Channing J; Singh, Mallika; Olive, Kenneth P
PMID: 39533066
ISSN: 1476-4687
CID: 5787002

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Wasko, Urszula N; Jiang, Jingjing; Dalton, Tanner C; Curiel-Garcia, Alvaro; Edwards, A Cole; Wang, Yingyun; Lee, Bianca; Orlen, Margo; Tian, Sha; Stalnecker, Clint A; Drizyte-Miller, Kristina; Menard, Marie; Dilly, Julien; Sastra, Stephen A; Palermo, Carmine F; Hasselluhn, Marie C; Decker-Farrell, Amanda R; Chang, Stephanie; Jiang, Lingyan; Wei, Xing; Yang, Yu C; Helland, Ciara; Courtney, Haley; Gindin, Yevgeniy; Muonio, Karl; Zhao, Ruiping; Kemp, Samantha B; Clendenin, Cynthia; Sor, Rina; Vostrejs, William P; Hibshman, Priya S; Amparo, Amber M; Hennessey, Connor; Rees, Matthew G; Ronan, Melissa M; Roth, Jennifer A; Brodbeck, Jens; Tomassoni, Lorenzo; Bakir, Basil; Socci, Nicholas D; Herring, Laura E; Barker, Natalie K; Wang, Junning; Cleary, James M; Wolpin, Brian M; Chabot, John A; Kluger, Michael D; Manji, Gulam A; Tsai, Kenneth Y; Sekulic, Miroslav; Lagana, Stephen M; Califano, Andrea; Quintana, Elsa; Wang, Zhengping; Smith, Jacqueline A M; Holderfield, Matthew; Wildes, David; Lowe, Scott W; Badgley, Michael A; Aguirre, Andrew J; Vonderheide, Robert H; Stanger, Ben Z; Baslan, Timour; Der, Channing J; Singh, Mallika; Olive, Kenneth P
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations1,2. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS and NRAS, with affinity for both mutant and wild-type variants3. More than 90% of cases of human pancreatic ductal adenocarcinoma (PDAC) are driven by activating mutations in KRAS4. Here we assessed the therapeutic potential of RMC-7977 in a comprehensive range of PDAC models. We observed broad and pronounced anti-tumour activity across models following direct RAS inhibition at exposures that were well-tolerated in vivo. Pharmacological analyses revealed divergent responses to RMC-7977 in tumour versus normal tissues. Treated tumours exhibited waves of apoptosis along with sustained proliferative arrest, whereas normal tissues underwent only transient decreases in proliferation, with no evidence of apoptosis. In the autochthonous KPC mouse model, RMC-7977 treatment resulted in a profound extension of survival followed by on-treatment relapse. Analysis of relapsed tumours identified Myc copy number gain as a prevalent candidate resistance mechanism, which could be overcome by combinatorial TEAD inhibition in vitro. Together, these data establish a strong preclinical rationale for the use of broad-spectrum RAS-GTP inhibition in the setting of PDAC and identify a promising candidate combination therapeutic regimen to overcome monotherapy resistance.
PMID: 38588697
ISSN: 1476-4687
CID: 5775732

Trends in the Care of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy

Thomas, Alexander S; Tehranifar, Parisa; Kwon, Wooil; Shridhar, Nupur; Sugahara, Kazuki N; Schrope, Beth A; Chabot, John A; Manji, Gulam A; Genkinger, Jeanine M; Kluger, Michael D
INTRODUCTION/BACKGROUND:Current guidelines for treatment for locally advanced pancreatic cancer recommend chemotherapy ± radiation, or radiation alone when multimodal therapy is contraindicated. In a subset of patients, guideline-recommended treatment (GRT) achieves sufficient response to qualify for potentially curative resection. This study evaluated trends in treatment utilization and aimed to identify barriers to GRT. METHODS:Patients with clinical T4M0 disease in the National Cancer Database from 2010 to 2017 were included. Potential predictors were assessed by relative risk regression with Poisson distribution and compared by log-link function. RESULTS:In total, 28 056 patients met the criteria. Among 17 059 (67.67%) patients treated primarily with chemotherapy, 41.19% also had radiation and 8.89% went onto resection. Many received no cancer-directed treatment or failed to receive GRT. Another 710 patients had radiation (±surgery) without chemotherapy despite few contraindications to chemotherapy. Over time, patients were more likely to undergo resection after chemotherapy (aRR = 1.58; p < 0.0001) and less likely to have chemoradiation (aRR = 0.78; p < 0.0001) or go untreated (aRR = 0.90; p < 0.0001). Socioeconomic factors (race, education, income, and insurance status) affected the likelihood of receiving chemotherapy and surgery. Median overall survival (OS) was significantly improved for patients treated with chemotherapy and particularly in those patients who went on to receive RT or undergo surgical resection. OS was also longer for patients treated at high-volume academic centers. Patients insured by Medicaid, Medicare, or those without insurance had worse OS. CONCLUSIONS:Despite improvement over time, many patients go untreated. Clinical factors were influential, but the impact of vulnerable social standing suggests persistent inequity in access to care.
PMID: 39348434
ISSN: 1096-9098
CID: 5775742

Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Registry Study

Martin, Robert C G; White, Rebekah Ruth; Bilimoria, Malcolm M; Kluger, Michael D; Iannitti, David A; Polanco, Patricio M; Hammil, Chet W; Cleary, Sean P; Heithaus, Robert Evans; Welling, Theodore; Chan, Carlos H F
BACKGROUND/OBJECTIVES/OBJECTIVE:Overall survival for patients with Stage 3 pancreatic ductal adenocarcinoma (PDAC) remains limited, with a median survival of 12 to 15 months. Irreversible electroporation (IRE) is a local tumor ablation method that induces cancerous cell death by disrupting cell membrane homeostasis. The DIRECT Registry study was designed to assess the effectiveness and safety of IRE when combined with standard of care (SOC) treatment for Stage 3 PDAC versus SOC alone in a real-world setting after at least 3 months of induction chemotherapy; Methods: Patients with Stage 3 PDAC treated with IRE plus SOC or SOC alone were prospectively enrolled in a multicenter registry study. Enrollment required 3 months of active multi-agent chemotherapy with no progression before enrollment. Endpoints were 30- and 90-day mortality and adverse events (AEs). RESULTS:= 0.0066). All IRE procedures were performed using an open approach. The 90-day all-cause mortality was 5/83 (6.0%) and 2/27 (7.4%) for the IRE and SOC groups, respectively. Two subjects in the IRE group died from treatment-related complications, and one patient in the SOC group died due to chemotherapy-related complications. CONCLUSIONS:Initial results from the DIRECT registry study indicate the use of IRE for curative intent tumor ablation in combination with induction chemotherapy has equivalent morbidity and mortality rates when compared to standard-of-care chemotherapy alone.
PMCID:11640091
PMID: 39682087
ISSN: 2072-6694
CID: 5764252

A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Mundi, Prabhjot S; Dela Cruz, Filemon S; Grunn, Adina; Diolaiti, Daniel; Mauguen, Audrey; Rainey, Allison R; Guillan, Kristina; Siddiquee, Armaan; You, Daoqi; Realubit, Ronald; Karan, Charles; Ortiz, Michael V; Douglass, Eugene F; Accordino, Melissa; Mistretta, Suzanne; Brogan, Frances; Bruce, Jeffrey N; Caescu, Cristina I; Carvajal, Richard D; Crew, Katherine D; Decastro, Guarionex; Heaney, Mark; Henick, Brian S; Hershman, Dawn L; Hou, June Y; Iwamoto, Fabio M; Jurcic, Joseph G; Kiran, Ravi P; Kluger, Michael D; Kreisl, Teri; Lamanna, Nicole; Lassman, Andrew B; Lim, Emerson A; Manji, Gulam A; McKhann, Guy M; McKiernan, James M; Neugut, Alfred I; Olive, Kenneth P; Rosenblat, Todd; Schwartz, Gary K; Shu, Catherine A; Sisti, Michael B; Tergas, Ana; Vattakalam, Reena M; Welch, Mary; Wenske, Sven; Wright, Jason D; Canoll, Peter; Hibshoosh, Hanina; Kalinsky, Kevin; Aburi, Mahalaxmi; Sims, Peter A; Alvarez, Mariano J; Kung, Andrew L; Califano, Andrea
UNLABELLED:Predicting in vivo response to antineoplastics remains an elusive challenge. We performed a first-of-kind evaluation of two transcriptome-based precision cancer medicine methodologies to predict tumor sensitivity to a comprehensive repertoire of clinically relevant oncology drugs, whose mechanism of action we experimentally assessed in cognate cell lines. We enrolled patients with histologically distinct, poor-prognosis malignancies who had progressed on multiple therapies, and developed low-passage, patient-derived xenograft models that were used to validate 35 patient-specific drug predictions. Both OncoTarget, which identifies high-affinity inhibitors of individual master regulator (MR) proteins, and OncoTreat, which identifies drugs that invert the transcriptional activity of hyperconnected MR modules, produced highly significant 30-day disease control rates (68% and 91%, respectively). Moreover, of 18 OncoTreat-predicted drugs, 15 induced the predicted MR-module activity inversion in vivo. Predicted drugs significantly outperformed antineoplastic drugs selected as unpredicted controls, suggesting these methods may substantively complement existing precision cancer medicine approaches, as also illustrated by a case study. SIGNIFICANCE:Complementary precision cancer medicine paradigms are needed to broaden the clinical benefit realized through genetic profiling and immunotherapy. In this first-in-class application, we introduce two transcriptome-based tumor-agnostic systems biology tools to predict drug response in vivo. OncoTarget and OncoTreat are scalable for the design of basket and umbrella clinical trials. This article is highlighted in the In This Issue feature, p. 1275.
PMCID:10239356
PMID: 37061969
ISSN: 2159-8290
CID: 5786922

The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score-matched analyses

Yun, Won-Gun; Han, Youngmin; Lee, Mirang; Cho, Young Jae; Jung, Hye-Sol; Thomas, Alexander S; Kluger, Michael D; Kwon, Wooil; Jang, Jin-Young
BACKGROUND:In an era of more effective chemotherapy for pancreatic ductal adenocarcinoma (PDAC), the paradigm of local treatment is changing. However, the efficacy of local treatment in patients with isolated liver metastasis remains unclear. Therefore, we aimed to evaluate the effectiveness of pancreatectomy ± local treatment for metastasis (cytoreductive surgery) in PDAC patients with isolated synchronous liver metastasis. METHODS:In total, 239 patients with isolated liver metastasis were extracted from Seoul National University Hospital (SNUH). For comparison, another 12 637 patients were extracted from the National Cancer Database (NCDB). Propensity score matching was performed to minimize confounding in both cohorts. Survival analyses stratified by the treatment delivered were performed using Kaplan-Meier estimates and log-rank tests. RESULTS:In the SNUH cohort, the median (interquartile range) survival was 20.5 (13.0-42.0) months for patients who underwent cytoreductive surgery plus chemotherapy versus 12.0 (10.0-18.0) months for those who received chemotherapy alone (P < .001). With the NCDB cohort, the median (interquartile range) survival was 15.6 (8.9-31.2) months for patients who underwent cytoreductive surgery plus chemotherapy versus 7.4 (3.4-13.2) months for those who received chemotherapy alone (P < .001). CONCLUSION/CONCLUSIONS:Patients with isolated synchronous liver metastasis should be considered for cytoreductive surgery in addition to effective chemotherapy.
PMID: 36734117
ISSN: 1868-6982
CID: 5786902

High rate of stone-related complications after stapling the cystic duct during laparoscopic cholecystectomy-an underrecognized risk

Thomas, Alexander S; Gleit, Zachary; Younan, Stephanie; Genkinger, Jeanine; Kluger, Michael D
BACKGROUND:Laparoscopic staplers (LS) have been suggested as a safe alternative to metal clips in laparoscopic cholecystectomy when the cystic duct is too inflamed or wide for complete clip occlusion. We aimed to evaluate the perioperative outcomes of patients whose cystic ducts were controlled by LS and evaluate the risk factors for complications. METHODS:Patients who underwent laparoscopic cholecystectomy with LS used to control the cystic duct from 2005 to 2019 were retrospectively identified from an institutional database. Patients were excluded for open cholecystectomy, partial cholecystectomy, or cancer. Potential risk factors for complications were assessed using logistic regression analysis. RESULTS:Among 262 patients, 191 (72.9%) were stapled for size and 71 (27.1%) for inflammation. In total, 33 (16.3%) patients had Clavien-Dindo grade ≥ 3 complications, with no significant difference when surgeons chose to staple for duct size versus inflammation (p = 0.416). Seven patients had bile duct injury. A large proportion had Clavien-Dindo grade ≥ 3 postoperative complications specifically related to bile duct stones [n = 29 (11.07%)]. Intraoperative cholangiogram was protective against postoperative complications [odds ratio (OR) = 0.18 (p = 0.022)]. CONCLUSION:Whether these high complication rates reflect a technical issue with stapling, more challenging anatomy, or worse disease, findings question whether the use of LS during laparoscopic cholecystectomy is truly a safe alternative to the already accepted methods of cystic duct ligation and transection. Based on these findings, an intraoperative cholangiogram should be performed when considering a linear stapler during laparoscopic cholecystectomy to: (1) ensure the biliary tree is free of stones; (2) prevent inadvertent transection of the infundibulum rather than the cystic duct; and, (3) allow opportunity for safe alternative strategies when an IOC is not able to confirm anatomy. Otherwise, surgeons employing LS devices should be aware that patients are at higher risk for complications.
PMID: 36890412
ISSN: 1432-2218
CID: 5786912

Contemporary practice and perception of autologous blood salvage in hepato-pancreatico-biliary operations: an international survey

Thomas, Alexander S; Belli, Andrea; Salceda, Juan; López-Ben, Santiago; Lee, Ser Y; Kwon, Wooil; Pawlik, Timothy M; Kluger, Michael D
BACKGROUND:This study aimed to assess contemporary knowledge, attitudes and behaviors around transfusion of intraoperative salvaged blood (sRBCt) during hepato-pancreatico-biliary (HPB) operations. Findings are meant to inform the design of future studies that address provider concerns to change behaviors and improve patient outcomes. METHODS:A survey was designed and assessed for relevance, readability and content, and distributed to an international audience of surgeons performing HPB operations. RESULTS:The 237 respondents were predominantly distributed across North America (37.55%), Europe (27.43%) and Asia (19.83%). Roughly one-half (52.74%) of respondents had used sRBCt in HPB surgery before. Transplantation surgeons were more likely than HPB surgeons to have previously used sRBCt [odds ratio = 5.18 (95% CI 1.89-14.20)]. More respondents believed sRBCt was safe for non-cancer versus cancer operations (68.57% vs. 24.17%, p < 0.0001). Less than half (45.71%) of respondents believed that sRBCt was safe in clean-contaminated fields. Most did not utilize preoperative strategies to avoid donor transfusion. CONCLUSION:Practices related to sRBCt in HPB operations vary widely and there is no consensus on its use. Concerns seem primarily related to cancer-specific and infectious outcomes. While further studies are pursued, surgeons may increase their utilization of preoperative strategies to boost hemoglobin levels for at risk patients.
PMID: 37117066
ISSN: 1477-2574
CID: 5786932